Instylla delivers next-generation liquid embolics for interventional radiology focused on interventional oncology and peripheral hemostasis.
Location: United States, Massachusetts, Bedford
Employees: 11-50
Total raised: $55.4M
Founded date: 2017
Investors 3
| Date | Name | Website |
| - | Excelestar... | excelestar... |
| - | Ascension ... | ascensionv... |
| - | Catalyst H... | chv.vc |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 26.08.2023 | - | $30M | - |
| 15.10.2020 | Series B | $25.4M | - |
Mentions in press and media 8
| Date | Title | Description |
| 28.01.2025 | FDA clears Instylla’s Tembo Embolic System | Instylla’s Tembo Embolic System [Image courtesy of Instylla]Instylla today said it has won FDA 510(k) clearance for its Tembo Embolic System. Bedford, Massachusetts-based Instylla said the Tembo system is a bioresorbable embolization agent ... |
| 26.08.2023 | Instylla Announces $30M Funding | BEDFORD, MA, Instylla, a company developing next-generation liquid embolics, announced the closing of a $30 million financing round. >> Click here for more funding data on Instylla >> To export Instylla funding data to PDF a... |
| 16.08.2023 | Instylla Closes $30M Equity Financing | Instylla, Inc., a Bedford, MA-based company developing next-generation liquid embolics for peripheral vascular embolotherapy, closed a $30m financing round. This round was led by new investor Delos Capital, with continued participation from... |
| 30.03.2021 | Instylla Announces Enrollment of Initial Patients in the Embrace™ Hydrogel Embolic System Global Randomized Multi-Center Clinical Trial | |
| 15.10.2020 | Instylla Closes $25.4M Series B Financing | Instylla, Inc., a Bedford, Mass.-based company developing minimally invasive liquid embolic products designed for use in peripheral vascular embolotherapy, closed a $25.4 million Series B financing. Backers included new investors Excelestar... |
| 15.10.2020 | Instylla Scores $25.4M Series B Financing | BEDFORD, MA, Instylla has announced a $25.4 million Series B financing. >> Click here for more funding data on Instylla >> To export Instylla funding data to PDF and Excel, click here Instylla, a privately held company de... |
| 14.10.2020 | Instylla Closes $25.4M Series B Financing | Instylla, Inc., a privately held company developing minimally invasive liquid embolic products designed for use in peripheral vascular embolotherapy today announced closure of $25.4 million Series B financing. Participants in this latest ro... |
| - | Instylla | “Instylla delivers next-generation liquid embolics for interventional radiology focused on interventional oncology and peripheral hemostasis.” |